Actively Recruiting
Differences by Sex and Genotype in the Effects of Stress on Executive Functions
Led by University of British Columbia · Updated on 2024-05-08
146
Participants Needed
1
Research Sites
344 weeks
Total Duration
On this page
Sponsors
U
University of British Columbia
Lead Sponsor
N
National Institute on Drug Abuse (NIDA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The aim of this project is to test the effects of an environmental factor (mild stress) on prefrontal cortex (PFC) and the cognitive functions that depend on PFC (collectively called executive functions \[EFs\]), and to test our predictions concerning how those effects differ by biological factors (hormones and genotype). To test our hypotheses concerning mechanism, the investigators will model the effects of mild stress on EFs pharmacologically. The purpose is to pharmacologically model the effects of mild stress on the cognitive functions (collectively called "executive functions" \[EFs\]) dependent on the frontal lobe. The investigators would also like to investigate how gender differences and genotype mediate the effect of methylphenidate (MPH) on EFs.
CONDITIONS
Official Title
Differences by Sex and Genotype in the Effects of Stress on Executive Functions
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Between the ages of 20 and 35 years old
You will not qualify if you...
- Having a neurological impairment, learning disability, or psychological syndrome that might affect executive function performance (such as ADHD)
- Inability to understand English instructions, or difficulty hearing, seeing stimuli, or responding manually
- History of serious adverse events during pregnancy or birth
- Injury affecting executive function (e.g., head injury with loss of consciousness)
- Major trauma affecting current executive functions and stress response
- Experiencing undue current life stress
- Taking medications that affect thinking, memory, mental clarity, or executive function abilities
- Taking medications that influence circulating gonadal hormone levels (e.g., oral contraceptives) or having taken such medications within the last four months
- Smoking
- Use of recreational drugs or alcohol consumption within 24 hours before testing sessions
- Women without a roughly monthly menstrual period
- Women who are pregnant or nursing
- Having glaucoma
- Having a heart condition
- Being anxious, tense, or agitated
- Taking or having taken within 14 days monoamine oxidase inhibitors (MAOI) antidepressants
- Taking pressor agents for hypotension
- Taking coumarin anticoagulants
- Taking anticonvulsants such as phenobarbital, diphenylhydantoin, or primidone
- Taking phenylbutazone (a nonsteroidal anti-inflammatory drug)
- Taking tricyclic antidepressants (imipramine, desipramine)
- Taking cold or allergy medicines containing decongestants
- Allergy to ingredients in MPH or Vitamin C capsules (methylphenidate HCL, ascorbic acid, lactose, gelatin, Titanium dioxide, D&C Red #28, FD&C Blue #1, FD&C Red #40)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Developmental Cognitive Neuroscience Lab, Department of Psychiatry, University of British Columbia
Vancouver, British Columbia, Canada, V6T 2A1
Actively Recruiting
Research Team
D
Daphne Ling, BSc
CONTACT
D
David Abbott, BSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here